Kringle Pharma, Inc.
Stock Price Chart
2026/10/09 19:27 UpdatedPrice Trend
2026/10/09 19:27 UpdatedPrice & Trading Details
2026/10/09 19:27 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/10/01Financial Performance
2026/10/04 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥392M | ¥69M | ¥80M | ¥72M |
| Gross Profit | ¥303M | ¥69M | ¥80M | ¥72M |
| Operating Income | -¥426M | -¥889M | -¥818M | -¥909M |
| Pretax Income | -¥426M | -¥889M | -¥818M | -¥909M |
| Net Income | -¥332M | -¥854M | -¥756M | -¥916M |
| EPS | -¥68.33 | -¥158.46 | -¥118.21 | -¥133.92 |
| Operating Margin | -108.76% | -1,283.41% | -1,021.87% | -1,259.37% |
| Balance Sheet | ||||
| Total Assets | ¥3,209M | ¥2,619M | ¥2,757M | ¥2,079M |
| Total Equity | ¥2,789M | ¥2,022M | ¥2,108M | ¥1,309M |
| Total Liabilities | ¥420M | ¥597M | ¥649M | ¥770M |
| Cash | ¥2,756M | ¥2,136M | ¥2,313M | ¥1,619M |
| Interest-bearing Debt | - | - | - | - |
| Equity Ratio | 86.93% | 77.20% | 76.46% | 62.96% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | ||||
| Operating CF | ¥16M | -¥689M | -¥661M | -¥756M |
| Investing CF | -¥254M | -¥121M | -¥121M | -¥154M |
| Financing CF | ¥603M | ¥69M | ¥838M | ¥84M |
| Free CF | ¥16M | -¥689M | -¥661M | -¥756M |
| Efficiency | ||||
| ROE | -11.90% | -42.25% | -35.88% | -69.98% |
| ROA | -10.34% | -32.62% | -27.44% | -44.06% |
Latest IR Information
-
Oremepermin alfa IND filing in the United States FDA
Submission of IND application to the U.S. FDA for orempermin alfa. Following Phase III in Japan, this milestone is key for global expansion.
Read more -
Notice of Revisions to Earnings Guidance for the Fiscal Year Ending September 2026
Revised earnings forecast for the fiscal year ending September 2026. Revenue increased from the previous forecast of 332 million to 442 million yen; operating income improved from △1,018 million to △800 million; ordinary income from △1,018 million to △796 million;...
Read more -
Notice Regarding the Introduction of the Executive Officer System
Starting October 1, 2026, the executive officer system will be introduced. The CEO will be the chief operating officer, with multiple executive officers appointed and currently held positions concurrently, and restricted stock units will be granted as compensation.
Read more -
Announcement of Joint Research with Yokohama City University
Signed a joint research agreement with Yokohama City University, a public university corporation. Conducting efficacy evaluation of HGF for CIPN. Describes only a minor impact on business performance from R&D expenses.
Read more -
A research project on the application of HGF to idiopathic femoral head necrosis has been adopted for AMED project
A joint research project with Gifu University School of Medicine has been adopted by AMED’s Practical Research for Intractable Disease program, accelerating preparation for a phase 1 clinical trial of Oremerumarin Alpha (HGF protein therapeutic). Non-clinical/preclinical data gathering will be...
Read more
Latest News (5 items)
Company Information
About
Kringle Pharma, Inc. engages in research and develops therapeutic agents for the treatment of intractable diseases in Japan. The company develops HGF products for the treatment of acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scar, and acute kidney injury. Kringle Pharma, Inc. was incorporated in 2001 and is based in Kita, Japan.
